NCT02166905View on ClinicalTrials.gov

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 10, 2014

Primary Completion Date

August 20, 2020

Study Completion Date

August 20, 2020

Conditions
Fallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma
Interventions
BIOLOGICAL

DEC-205/NY-ESO-1 Fusion Protein CDX-1401

Given via intracutaneous injection

DRUG

Epacadostat

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Poly ICLC

Given SC

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Celldex Therapeutics

INDUSTRY

collaborator

Incyte Corporation

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT02166905 - DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | Biotech Hunter | Biotech Hunter